{"id":70074,"date":"2026-07-16T15:55:48","date_gmt":"2026-07-16T07:55:48","guid":{"rendered":"https:\/\/flcube.com\/?p=70074"},"modified":"2026-07-16T15:55:50","modified_gmt":"2026-07-16T07:55:50","slug":"braveheart-bio-files-ipo-prospectus-with-nasdaq-for-1-8b-cardiac-myosin-inhibitor-asset","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70074","title":{"rendered":"Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Braveheart Bio<\/strong>, a Delaware-based biopharmaceutical company founded in 2024, submitted its <strong>IPO prospectus<\/strong> to the <strong>US Nasdaq<\/strong> on July 15, 2026, applying to list under the ticker symbol <strong>&#8220;BRVE.&#8221;<\/strong> The company plans to use offering proceeds to advance its lead asset, <strong>BHB-1893<\/strong> (formerly HRS-1893), a selective cardiac myosin inhibitor acquired from <strong>Hengrui Pharmaceuticals<\/strong> in a nearly <strong>USD 1.8 billion<\/strong> global rights deal.<\/p>\n\n\n\n<h2 id=\"h-corporate-profile-key-milestones\" class=\"wp-block-heading\">Corporate Profile | Key Milestones<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Milestone<\/th><th>Details<\/th><\/tr><\/thead><tbody><tr><td><strong>Company Formation<\/strong><\/td><td>Delaware, USA \u2013 2024<\/td><\/tr><tr><td><strong>Asset Acquisition<\/strong><\/td><td>September 2025 \u2013 Global rights to HRS-1893 from Hengrui Pharmaceuticals<\/td><\/tr><tr><td><strong>Acquisition Value<\/strong><\/td><td>Nearly USD 1.8 billion<\/td><\/tr><tr><td><strong>IPO Filing Date<\/strong><\/td><td>July 15, 2026<\/td><\/tr><tr><td><strong>Proposed Ticker<\/strong><\/td><td>BRVE (Nasdaq)<\/td><\/tr><tr><td><strong>Lead Asset<\/strong><\/td><td>BHB-1893 (cardiac myosin inhibitor)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-lead-asset-profile-bhb-1893\" class=\"wp-block-heading\">Lead Asset Profile: BHB-1893<\/h2>\n\n\n\n<h3 id=\"h-mechanism-of-action\" class=\"wp-block-heading\">Mechanism of Action<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Target:<\/strong> Cardiac myosin adenosine triphosphatase (ATPase)<\/li>\n\n\n\n<li><strong>Class:<\/strong> Selective myosin inhibitor<\/li>\n\n\n\n<li><strong>Therapeutic Effect:<\/strong><\/li>\n\n\n\n<li>Suppresses myocardial hypercontraction<\/li>\n\n\n\n<li>Reduces left ventricular hypertrophy<\/li>\n\n\n\n<li>Improves diastolic relaxation<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-clinical-development-status\" class=\"wp-block-heading\">Clinical Development Status<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication:<\/strong> Obstructive hypertrophic cardiomyopathy (oHCM)<\/li>\n\n\n\n<li><strong>Phase:<\/strong> Phase III clinical development<\/li>\n\n\n\n<li><strong>Origin:<\/strong> Self-developed by Hengrui Pharmaceuticals (600276.SH\/1276.HK)<\/li>\n\n\n\n<li><strong>Global Rights:<\/strong> Acquired by Braveheart Bio in September 2025<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-strategic-transaction-details\" class=\"wp-block-heading\">Strategic Transaction Details<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The September 2025 agreement with <strong>Hengrui Pharmaceuticals<\/strong> granted Braveheart Bio <strong>global development and commercialization rights<\/strong> to BHB-1893, representing one of the largest out-licensing deals by a Chinese pharmaceutical company to a US-based biotech startup. The nearly <strong>USD 1.8 billion<\/strong> valuation reflects the significant market potential in oHCM, a condition affecting approximately <strong>600,000-800,000 patients<\/strong> in the United States alone.<\/p>\n\n\n\n<h2 id=\"h-market-opportunity-amp-competitive-landscape\" class=\"wp-block-heading\">Market Opportunity &amp; Competitive Landscape<\/h2>\n\n\n\n<h3 id=\"h-obstructive-hypertrophic-cardiomyopathy-market\" class=\"wp-block-heading\">Obstructive Hypertrophic Cardiomyopathy Market<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Prevalence:<\/strong> Affects 1 in 500 people globally<\/li>\n\n\n\n<li><strong>Current Treatment Limitations:<\/strong> Primarily symptomatic management with beta-blockers and calcium channel blockers<\/li>\n\n\n\n<li><strong>Unmet Need:<\/strong> Disease-modifying therapies that address underlying pathophysiology<\/li>\n\n\n\n<li><strong>Market Size:<\/strong> Estimated at <strong>$2-3 billion annually<\/strong> in major markets<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-competitive-positioning\" class=\"wp-block-heading\">Competitive Positioning<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">BHB-1893 joins a select group of cardiac myosin inhibitors in development, including <strong>mavacamten<\/strong> (approved) and <strong>aficamten<\/strong> (Phase III). The asset&#8217;s differentiation will depend on its <strong>safety profile, dosing convenience, and efficacy<\/strong> in reducing left ventricular outflow tract gradients.<\/p>\n\n\n\n<h2 id=\"h-ipo-strategic-rationale\" class=\"wp-block-heading\">IPO Strategic Rationale<\/h2>\n\n\n\n<p class=\"wp-block-paragraph\">The public offering provides Braveheart Bio with capital to:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li>Complete <strong>Phase III clinical development<\/strong> of BHB-1893<\/li>\n\n\n\n<li>Support <strong>regulatory submissions<\/strong> in major markets (US, EU, China)<\/li>\n\n\n\n<li>Build <strong>commercial infrastructure<\/strong> for potential product launch<\/li>\n\n\n\n<li>Explore <strong>additional pipeline opportunities<\/strong> in cardiovascular diseases<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\">For Hengrui Pharmaceuticals, the transaction validates its innovative drug discovery capabilities and provides substantial non-dilutive funding while retaining no further development obligations.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward-Looking Statements<\/strong><br>This brief contains forward-looking statements regarding IPO plans, clinical development, and business strategy. Actual results may differ due to risks including regulatory decisions, clinical trial outcomes, market conditions, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,10],"tags":[4336,2586,72],"class_list":["post-70074","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-braveheart-bio","tag-hengrui-pharmaceuticals","tag-ipo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.0) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the US Nasdaq on July 15, 2026, applying to list under the ticker symbol &quot;BRVE.&quot; The company plans to use offering proceeds to advance its lead asset, BHB-1893 (formerly HRS-1893), a selective cardiac myosin inhibitor acquired from Hengrui Pharmaceuticals in a nearly USD 1.8 billion global rights deal.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70074\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset\" \/>\n<meta property=\"og:description\" content=\"Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the US Nasdaq on July 15, 2026, applying to list under the ticker symbol &quot;BRVE.&quot; The company plans to use offering proceeds to advance its lead asset, BHB-1893 (formerly HRS-1893), a selective cardiac myosin inhibitor acquired from Hengrui Pharmaceuticals in a nearly USD 1.8 billion global rights deal.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70074\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-16T07:55:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-16T07:55:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70074#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70074\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset\",\"datePublished\":\"2026-07-16T07:55:48+00:00\",\"dateModified\":\"2026-07-16T07:55:50+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70074\"},\"wordCount\":412,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Braveheart Bio\",\"Hengrui Pharmaceuticals\",\"IPO\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70074#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70074\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70074\",\"name\":\"Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-07-16T07:55:48+00:00\",\"dateModified\":\"2026-07-16T07:55:50+00:00\",\"description\":\"Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the US Nasdaq on July 15, 2026, applying to list under the ticker symbol \\\"BRVE.\\\" The company plans to use offering proceeds to advance its lead asset, BHB-1893 (formerly HRS-1893), a selective cardiac myosin inhibitor acquired from Hengrui Pharmaceuticals in a nearly USD 1.8 billion global rights deal.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70074#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70074\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70074#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset - Insight, China&#039;s Pharmaceutical Industry","description":"Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the US Nasdaq on July 15, 2026, applying to list under the ticker symbol \"BRVE.\" The company plans to use offering proceeds to advance its lead asset, BHB-1893 (formerly HRS-1893), a selective cardiac myosin inhibitor acquired from Hengrui Pharmaceuticals in a nearly USD 1.8 billion global rights deal.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70074","og_locale":"en_US","og_type":"article","og_title":"Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset","og_description":"Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the US Nasdaq on July 15, 2026, applying to list under the ticker symbol \"BRVE.\" The company plans to use offering proceeds to advance its lead asset, BHB-1893 (formerly HRS-1893), a selective cardiac myosin inhibitor acquired from Hengrui Pharmaceuticals in a nearly USD 1.8 billion global rights deal.","og_url":"https:\/\/flcube.com\/?p=70074","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-16T07:55:48+00:00","article_modified_time":"2026-07-16T07:55:50+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70074#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70074"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset","datePublished":"2026-07-16T07:55:48+00:00","dateModified":"2026-07-16T07:55:50+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70074"},"wordCount":412,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Braveheart Bio","Hengrui Pharmaceuticals","IPO"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70074#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70074","url":"https:\/\/flcube.com\/?p=70074","name":"Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-07-16T07:55:48+00:00","dateModified":"2026-07-16T07:55:50+00:00","description":"Braveheart Bio, a Delaware-based biopharmaceutical company founded in 2024, submitted its IPO prospectus to the US Nasdaq on July 15, 2026, applying to list under the ticker symbol \"BRVE.\" The company plans to use offering proceeds to advance its lead asset, BHB-1893 (formerly HRS-1893), a selective cardiac myosin inhibitor acquired from Hengrui Pharmaceuticals in a nearly USD 1.8 billion global rights deal.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70074#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70074"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70074#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Braveheart Bio Files IPO Prospectus with Nasdaq for $1.8B Cardiac Myosin Inhibitor Asset"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70074","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70074"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70074\/revisions"}],"predecessor-version":[{"id":70075,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70074\/revisions\/70075"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70074"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70074"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70074"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}